NDC 70710-2142-01
Carbidopa and Levodopa 61.25 mg/1, 245 mg/1 CAPSULE, EXTENDED RELEASE
Available — 2-Day Shipping
NDC
70710-2142-01
Generic Name
Carbidopa and Levodopa
Brand Name
Carbidopa and Levodopa
Strength
61.25 mg/1, 245 mg/1
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Package Size
—
Labeler
Zydus Pharmaceuticals USA Inc.
FDA Drug Information
Indications & Usage
1 INDICATIONS AND USAGE Carbidopa and levodopa extended-release capsules are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa and levodopa extended-release capsule is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism,…
Source: FDA. For professional use only. Not a substitute for prescribing information.
View Product Detail →
See full specifications, request 2-day shipping, and create account to view pricing
All Carbidopa and Levodopa Strengths & Forms →
Compare all available NDC codes, strengths, and manufacturers
Other Carbidopa and Levodopa NDC Codes
Wholesale and compliance resources
DSCSA compliance resource hubRead practical guidance for authorized partners, records, and traceability.Transaction information and statementsLearn about the records that accompany pharmaceutical transfers.ScriptTrack medication workflow softwareExplore the included starter workflow for verified businesses.
Order NDC 70710-2142-01 at Wholesale
Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).